A powerful flu shot may be the key to protecting our seniors, and it's not just for those with diabetes! But here's where it gets intriguing...
Study Unveils Surprising Results:
A recent study reveals that a high-dose inactivated influenza vaccine (HD-IIV) could be a game-changer for adults aged 65 and above. When compared to the standard-dose vaccine (SD-IIV), HD-IIV demonstrated a remarkable ability to reduce hospitalisations related to cardiorespiratory and cardiovascular issues, as well as influenza, regardless of whether the individuals had diabetes.
Methodology and Participants:
The DANFLU-2 trial, conducted over three influenza seasons from 2022/2023 to 2024/2025, delved into the effectiveness of HD-IIV versus SD-IIV in older adults. The study involved a substantial 332,438 participants, with an average age of 73.7 years, almost half of whom were women. These participants were randomly assigned to receive either the HD-IIV, containing a higher concentration of haemagglutinin antigen (60 μg per strain), or the SD-IIV (15 μg per strain).
The study also focused on a subset of 43,881 individuals with diabetes, identified through diagnostic codes or A1c levels over the past decade. The follow-up period was extensive, starting 14 days post-vaccination and continuing until May 31 of the subsequent year.
Key Findings:
The results were eye-opening! HD-IIV outperformed SD-IIV in reducing hospitalisations for various cardiorespiratory and cardiovascular diseases, as well as influenza, with or without laboratory confirmation. Interestingly, the benefits of HD-IIV were consistent for participants with or without diabetes when it came to cardiorespiratory disease hospitalisations. And the advantages didn't stop there; HD-IIV also showed superiority in reducing hospitalisations for cardiovascular diseases and influenza, irrespective of diabetes status.
But here's the twist: among participants with diabetes, those with a longer diabetes duration (over 5 years) seemed to gain more from HD-IIV in preventing cardiorespiratory disease hospitalisations.
Implications and Expert Insights:
The study authors emphasize the significance of these findings, suggesting that HD-IIV may offer advantages over SD-IIV for individuals with diabetes. This study, led by Dr. Anne Bjerg Nielsen from Copenhagen University Hospital, Denmark, was published in JAMA Internal Medicine on January 12, 2026.
Considerations and Limitations:
It's important to note that the DANFLU-2 trial was not specifically designed for subgroup analyses, so the findings are exploratory. The results should be interpreted considering the neutral primary outcome of hospitalisation for influenza or pneumonia. Additionally, the study may have underestimated diabetes duration due to potential earlier diagnoses outside the time frames used.
Funding and Disclosures:
This research was funded by Sanofi, and several authors disclosed connections to the company, including employment, shares, and stock options. Other authors reported financial ties to various pharmaceutical companies, including Sanofi.
And this is the part that sparks debate: How might these industry connections influence the interpretation of the study's results? Are there potential biases at play? Share your thoughts in the comments below!
